Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AAK1 | Q2M2I8 | 9/20 | 0.43 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.43 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.40 |
| ▸ | KCNQ4 | P56696 | 2/20 | 0.39 |
| ▸ | KCNQ5 | Q9NR82 | 2/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.38 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.38 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.37 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.37 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.37 |
| ▸ | BRAF | P15056 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3568182 | 0.88 | AAK1 (0.40) | AAK1CYP17A1RXFP1KCNQ4KCNQ5 | |
| SCHEMBL2353023 | 0.88 | AAK1 (0.40) | AAK1CYP17A1RXFP1KCNQ4KCNQ5 | |
| SCHEMBL5563358 | 0.87 | LMNA (0.44) | AAK1CYP17A1RXFP1LMNAPOLB | |
| SCHEMBL29430784 | 0.87 | LMNA (0.44) | AAK1CYP17A1RXFP1LMNAPOLB | |
| SCHEMBL25380050 | 0.87 | AAK1 (0.47) | AAK1CYP17A1 | |
| SCHEMBL6164977 | 0.86 | AAK1 (0.38) | AAK1CYP17A1RXFP1KCNQ4KCNQ5 | |
| SCHEMBL14725520 | 0.85 | CYP17A1 (0.48) | AAK1CYP17A1RXFP1KCNQ4KCNQ5 | |
| SCHEMBL20096641 | 0.84 | TRPA1 (0.46) | AAK1CYP17A1RXFP1KCNQ4KCNQ5 | |
| SCHEMBL29430592 | 0.84 | TRPA1 (0.46) | AAK1CYP17A1RXFP1KCNQ4KCNQ5 | |
| SCHEMBL197145 | 0.84 | HDAC1 (0.55) | AAK1CYP17A1KCNQ4KCNQ5HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2526096-B1 | 4-PHENOXY-NICOTINAMIDE OR 4-PHENOXY-PYRIMIDINE-5-CARBOXAMIDE COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2015-04-22 | — | — | EP | disclosed |
| US-8729091-B2 | 4-phenoxy-nicotinamide or 4-phenoxy-pyrimidine-5-carboxamide compounds | HOFFMANN-LA ROCHE INC. (US) | 2014-05-20 | — | — | US | disclosed |
| EP-2350022-B1 | NEW BENZIMIDAZOLE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2013-11-20 | — | — | EP | disclosed |
| US-20130150372-A1 | 4-PHENOXY-NICOTINAMIDE OR 4-PHENOXY-PYRIMIDINE-5-CARBOXAMIDE COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2013-06-13 | — | — | US | disclosed |
| US-8420647-B2 | 4-phenoxy-nicotinamide or 4-phenoxy-pyrimidine-5-carboxamide compounds | HOFFMANN-LA ROCHE INC. (US) | 2013-04-16 | — | — | US | disclosed |
| EP-2321282-B1 | NEW BENZIMIDAZOLE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2013-03-27 | — | — | EP | disclosed |
| EP-2222645-B1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS FXR AGONISTS | HOFFMANN LA ROCHE (CH) | 2013-03-20 | — | — | EP | disclosed |
| EP-2188263-B1 | BENZIMIDAZOLE DERIVATIVES USED AS FXR AGONISTS | HOFFMANN LA ROCHE (CH) | 2012-06-27 | — | — | EP | disclosed |
| US-8143422-B2 | Benzimidazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2012-03-27 | — | — | US | disclosed |
| US-8088930-B2 | Benzimidazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2012-01-03 | — | — | US | disclosed |
| US-20100063101-A1 | NEW BENZIMIDAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2010-03-11 | — | — | US | disclosed |
| US-7645785-B2 | Benzimidazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2010-01-12 | — | — | US | disclosed |
| WO-2009080555-A2 | CARBOXYL- OR HYDROXYL- SUBSTITUTED BENZIMIDAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-07-02 | — | — | WO | disclosed |
| US-20090163552-A1 | CARBOXYL- OR HYDROXYL-SUBSTITUTED BENZIMIDAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2009-06-25 | — | — | US | disclosed |
| WO-2009062874-A2 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS FXR AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-05-22 | — | — | WO | disclosed |
| US-20090131482-A1 | METHYL-BENZIMIDAZOLE DERIVATIVES | HOFFMANN-LA ROCHE, INC. | 2009-05-21 | — | — | US | disclosed |
| EP-2038259-A1 | BENZIMIDAZOLE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, THEIR USE AS FXR AGONISTS AND PHARMACEUTICAL PREPARATIONS CONTAINING THE SAME | F.HOFFMANN-LA ROCHE AG (CH) | 2009-03-25 | — | — | EP | disclosed |
| US-20090062356-A1 | SUBSTITUTED BENZIMIDAZOLE DERIVATIVES | HOFFMANN-LA ROCHE, INC. | 2009-03-05 | — | — | US | disclosed |
| US-20080021027-A1 | Novel benzimidazole derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2008-01-24 | — | — | US | disclosed |
| WO-2008000643-A1 | BENZIMIDAZOLE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, THEIR USE AS FXR AGONISTS AND PHARMACEUTICAL PREPARATIONS CONTAINING THE SAME | F. HOFFMANN-LA ROCHE AG (CH) | 2008-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100063101-A1 | NEW BENZIMIDAZOLE DERIVATIVES | CYP3A7, ECI1, CYP2B6 | AAK1 3559/4885CYP17A1 2458/4885RXFP1 1854/4885 |
| US-20090062356-A1 | SUBSTITUTED BENZIMIDAZOLE DERIVATIVES | NR1H4, SLC10A1, FXR1 | AAK1 3523/4885CYP17A1 675/4885RXFP1 401/4885 |
| US-20130150372-A1 | 4-PHENOXY-NICOTINAMIDE OR 4-PHENOXY-PYRIMIDINE-5-CARBOXAMIDE COMPOUNDS | P2RY1, GPBAR1, ADORA1 | AAK1 1816/4885CYP17A1 3496/4885RXFP1 315/4885 |
| US-20080021027-A1 | Novel benzimidazole derivatives | NR1H4, GPR119, GLP1R | AAK1 2309/4885CYP17A1 873/4885RXFP1 99/4885 |
| US-20090131482-A1 | METHYL-BENZIMIDAZOLE DERIVATIVES | HDAC10, CYP3A4, ECI1 | AAK1 4239/4885CYP17A1 1522/4885RXFP1 1518/4885 |
| US-20090163552-A1 | CARBOXYL- OR HYDROXYL-SUBSTITUTED BENZIMIDAZOLE DERIVATIVES | NR1H4, GPBAR1, SLC10A1 | AAK1 4069/4885CYP17A1 759/4885RXFP1 309/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.